Why did Moderna's stock more than double on Wednesday?

Moderna's shares more than doubled after promising late-stage clinical trial data showed its personalized mRNA cancer vaccine, intismeran, reduced the risk of recurrence and spread of skin cancer when combined with Merck's Keytruda—marking a pivotal validation of mRNA technology beyond infectious diseases and triggering massive investor buying and short-covering pressure.

What is the significance of the cancer vaccine intismeran for Moderna's long-term strategy?

Intismeran is central to Moderna's effort to prove its mRNA platform can succeed beyond its COVID-19 vaccine franchise and infectious disease shots, helping the company build a more durable revenue base—especially as it expands into flu, norovirus, and Lyme disease vaccines, and seeks commercial validation in oncology.

Moderna shares double as cancer vaccine data rekindles investor hopes

Aug 19, 2026

Moderna shares surged over 100% following positive late-stage data showing its mRNA cancer therapy with Merck reduced skin cancer recurrence. Analysts project $1.4 billion in sales potential by 2032, signaling strong growth beyond infectious disease vaccines.

reuters

2026-08-19

Moderna shares double as cancer vaccine data rekindles investor hopes

Moderna shares double as cancer vaccine data rekindles investor hopes

FAQ